Acellular pertussis vaccines and the role of pertactin and fimbriae.
The introduction of acellular pertussis (Pa) vaccines in countries with a low uptake of whole-cell pertussis (Pw) vaccines has led to a dramatic reduction in pertussis disease. Diphtheria-tetanus-acellular pertussis (DTPa) vaccines have also ensured continued high level disease protection in these countries following the shift from Pw- to Pa-containing vaccines, and allowed pertussis booster programs to be implemented. Vaccines containing between one and five components have been licensed and implemented. Those with three or more components consisting of filamentous hemagglutinin (FHA), pertussis toxin (PT) and pertactin (PRN) are considered to be more effective than one/two-component Pa vaccines that contain only PT or both PT and FHA. Changes in circulating Bordetella pertussis strains may impact vaccine efficacy and, thus, incidence and transmission of pertussis and deserve to be followed carefully. To date, vaccine-induced shifts among fimbriae (FIM) are reported and this could impact the efficacy of FIM-containing vaccines. Currently, FIM3 appears to be dominant in most European countries, Canada and Australia. Data obtained from a DTPa5 vaccine containing FIM2 and FIM3 have indicated a shift towards an increase in FIM3-expressing B. pertussis clinical breakthrough cases when compared with control vaccine. By contrast, relatively minor PT and PRN sequence polymorphisms have been identified without demonstrable association with vaccination programs. Adsorption of PRN to aluminum salt appears critical for optimal protective capacity in murine pertussis lung challenge. In addition, clinical studies have shown anti-PRN antibody levels to be higher when PRN is adsorbed at a 8-microg dosage versus non-adsorbed PRN at a 3-microg dosage. The available data, therefore, demonstrate that appropriately formulated acellular vaccines containing PT and PRN are the preferred option for pertussis immunization.
Poolman
Jan T
JT
Head of Bacterial Vaccines, R&D Bacterial Vaccine Program, GlaxoSmithKline Biologicals, Rixensart, Belgium. jan.poolman@gskbio.com
Hallander
Hans O
HO
D001425:Bacterial Outer Membrane Proteins / Q000502:physiology*; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines / Q000627:therapeutic use*; D010861:Fimbriae, Bacterial / Q000502:physiology*; D006801:Humans; D010567:Pertussis Vaccine / Q000627:therapeutic use*; D010566:Virulence Factors, Bordetella; D014917:Whooping Cough / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control*
D001425:Bacterial Outer Membrane Proteins; D022681:Diphtheria-Tetanus-acellular Pertussis Vaccines; D010567:Pertussis Vaccine; D010566:Virulence Factors, Bordetella; C068929:pertactin